Literature DB >> 14675601

Natural course of voiding function in patients with human T-cell lymphotrophic virus type 1-associated myelopathy.

Ken-ichi Mori1, Mitsuru Noguchi, Manabu Matsuo, Koichiro Nomata, Tatsufumi Nakamura, Hiroshi Kanetake.   

Abstract

OBJECTIVES: Patients with human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) frequently experience voiding dysfunction. In patients with HAM/TSP, the major symptoms are gait disturbance and voiding dysfunction. However, the detailed natural course of voiding function and the management of their urination has not previously been investigated. We examined the correlation between voiding function and clinical features and evaluated the management of urination, in the patients with HAM/TSP. PATIENTS AND METHODS: The voiding function of 47 patients (7 males, 40 females, aged 29-89 years, mean: 60.9 years) with HAM/TSP was analyzed retrospectively. All HAM/TSP patients are positive for HTLV-1. Patients were referred to a neurologist for analysis of bladder function. In the present study, we analyzed their clinical details, age at disease onset, voiding function and alterations in the management of their urination. Furthermore, we investigated the relationship between urological management and the clinical features of HAM/TSP.
RESULTS: Of the 47 patients, 20 (42.5%) were able to void with or without drug therapy. Thirty-four (72.3%) experienced clean intermittent self-catheterization (CIC), with 25 of these 34 continuing CIC, 7 changing to voiding and 2 changing to management with the Foley catheter. No relationship was noted between disruption of voiding function and either age or gender. However, significant inverse correlation was observed between the age at disease onset and the time to CIC (r=-0.77, P=0.00001).
CONCLUSIONS: These data suggest that the younger a patients is at HAM/TSP onset, the longer voiding function will be maintained.

Entities:  

Mesh:

Year:  2004        PMID: 14675601     DOI: 10.1016/j.jns.2003.08.004

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

Review 1.  Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.

Authors:  Denise Utsch Gonçalves; Fernando Augusto Proietti; João Gabriel Ramos Ribas; Marcelo Grossi Araújo; Sônia Regina Pinheiro; Antônio Carlos Guedes; Anna Bárbara F Carneiro-Proietti
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

2.  Isokinetic trunk and knee muscle strengths and gait performance in walking patients with T-cell lymphotropic virus type 1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP).

Authors:  Masashi Miyazaki; Harutoshi Sakakima; Tatsushi Goto; Ryoji Kiyama; Toshio Matsuzaki; Kosei Ijiri; Yoshihiro Yoshida
Journal:  J Jpn Phys Ther Assoc       Date:  2011

3.  Recurrent Spontaneous Rupture of the Urinary Bladder in a Patient With Human T-lymphotropic Virus Type 1-Associated Myelopathy: A Case Report and Literature Review.

Authors:  Behzad Feizzadeh Kerigh; Reza Boostani; Alireza Ghoreifi
Journal:  Nephrourol Mon       Date:  2014-02-02

4.  Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Natsuko Yamakawa; Naoko Yagishita; Tomohiro Matsuo; Junji Yamauchi; Takahiko Ueno; Eisuke Inoue; Ayako Takata; Misako Nagasaka; Natsumi Araya; Daisuke Hasegawa; Ariella Coler-Reilly; Shuntaro Tsutsumi; Tomoo Sato; Abelardo Araujo; Jorge Casseb; Eduardo Gotuzzo; Steven Jacobson; Fabiola Martin; Marzia Puccioni-Sohler; Graham P Taylor; Yoshihisa Yamano
Journal:  Orphanet J Rare Dis       Date:  2020-07-03       Impact factor: 4.123

5.  Bladder dysfunction in human T cell lymphotropic virus infection: A prospective cohort study.

Authors:  José Abraão Carneiro Neto; Cássius José Vitor de Oliveira; Sheila Nunes Ferraz; Mariele Guerra; Lívia Alves Oliveira; Lúcia Passos; Edgar M Carvalho; Paulo Novis Rocha
Journal:  PLoS Negl Trop Dis       Date:  2022-01-14

6.  Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder.

Authors:  Jose Abraão Carneiro Neto; Silvane Braga Santos; Gloria Orge Orge; Davi Tanajura; Lucia Passos; Cassius José Oliveira; Rosana Andrade; Cláudio Galeno de Melo; Ubirajara Barroso; Edgar M Carvalho
Journal:  Braz J Infect Dis       Date:  2018-02-17       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.